Hims vs. Keeps in 2026: Same Pills, Different Packaging, and What Actually Matters

For this comparison guide, context is the difference between useful guidance and another anxiety spiral. Pattern, density, age, family history, and treatment tolerance all matter before anyone jumps to a product or procedure.

A friend of mine, Danny, a 31-year-old marketing guy in Austin, texted me a screenshot last fall. He’d been toggling between the Hims and Keeps checkout pages on his phone for twenty minutes, genuinely confused. Both offered finasteride. Both offered minoxidil. Both had slick branding and telehealth consultations that took about as long as ordering a burrito on DoorDash. “Which one is the real one?” he asked. The answer, which he didn’t love, is that they’re both real. And the drugs are identical. The question he should have been asking was different entirely.

That’s the thing about the DTC hair loss market in 2026. The actual pharmacology hasn’t changed much since finasteride was approved in 1997. What’s changed is the packaging, the pricing psychology, and how easily you can start treatment without ever sitting across from someone who’s looked at ten thousand scalps. Whether that’s a feature or a bug depends on your situation.

The Biology Nobody Wants to Hear About (But Should)

Before comparing subscription boxes, it helps to understand what’s actually happening on your head.

Pattern hair loss runs on dihydrotestosterone (DHT), a potent androgen your body makes from testosterone via the enzyme 5-alpha reductase. In follicles that are genetically susceptible, DHT progressively shortens the growth phase and shrinks the dermal papilla itself. Thick terminal hairs become thin, wispy vellus hairs. Eventually some follicles stop producing visible hair altogether. This process is called follicular miniaturization, and once it’s advanced enough, no pill reverses it.

James Hamilton documented the androgen connection back in 1951 in the Annals of the New York Academy of Sciences, observing that men castrated before puberty never developed typical male pattern loss. O’Tar Norwood formalized the staging system in his 1975 Southern Medical Journal paper, expanding Hamilton’s framework into the seven-stage scale (plus variants) that dermatologists still use today. The Norwood scale has survived more than 70 years not because it’s perfect but because it’s practical. Newer systems like the BASP classification proposed in 2007 haven’t displaced it in routine clinical use.

The genetics are polygenic. Yes, the androgen receptor gene sits on the X chromosome, which is why people point to the maternal grandfather. But paternal contributions and multiple autosomal loci matter too. Family history is a clue, not a crystal ball.

What Finasteride and Minoxidil Actually Do

Two drugs carry the weight of the entire DTC hair loss industry.

Finasteride (1 mg daily) inhibits the type II isoform of 5-alpha reductase, lowering scalp DHT. The five-year randomized trial published in the Journal of the American Academy of Dermatology (JAAD) in 2002 showed sustained hair count improvements and better patient self-assessment versus placebo. Sexual side effects affect a small percentage of users in controlled trials and are generally reversible on discontinuation. Dutasteride, which blocks both type I and type II isoforms, lowers DHT more aggressively and has shown larger density improvements in head-to-head trials, though it’s prescribed off-label for hair loss.

Minoxidil (5% topical, applied twice daily) works through mechanisms that aren’t fully pinned down, involving potassium channel opening, vasodilation, and direct effects on the follicle that prolong the growth phase. Multiple randomized trials document visible results at three to six months. Low-dose oral minoxidil (0.25 to 5 mg daily) gained traction after Vañó-Galván et al. published their 1,404-patient multicenter study in JAAD in 2021, showing a more manageable side-effect profile at low doses than the original cardiovascular formulation. Periorbital edema and hypertrichosis still show up in some patients.

The boring truth: when Hims ships you finasteride, it’s the same molecule Keeps ships you. Same FDA-approved dose, same generic manufacturers, same mechanism. The differences are in subscription pricing, bundled formulations (some combination topicals, some oral-only plans), shipping logistics, and the quality of the telehealth consultation. For a detailed breakdown of how those differences shake out, this comparison guide lays out the staging reference and assessment workflow side by side.

What Treatment Costs (Without the Marketing Spin)

Let’s talk numbers, since both platforms lean hard on perceived value.

Generic oral finasteride 1 mg runs $10 to $25 per month at US pharmacies with common discount cards, and sometimes $5 to $15 through DTC services. Branded Propecia still costs $70 to $90 monthly with zero documented clinical advantage over the generic.

Generic topical minoxidil 5% costs $10 to $30 per month. Branded Rogaine roughly doubles that. Foam and solution are clinically equivalent; foam just irritates fewer scalps.

Low-dose oral minoxidil in generic form often comes in under $15 monthly. The real cost driver is the prescribing visit ($50 to $150 through telehealth, or covered by insurance through a regular derm appointment).

Hair transplantation is a different universe. FUE in the United States runs $4 to $10 per graft. A typical case of 2,500 to 3,500 grafts lands between $10,000 and $35,000. Turkish clinics price similar graft counts at $2,000 to $5,000 total, reflecting labor cost differences more than necessarily quality differences. PRP runs $500 to $1,500 per session, with most protocols calling for three to four sessions in year one. First-year PRP costs can match or exceed an entire year of combination medical therapy.

Insurance almost never covers any of this. Pattern hair loss is classified as cosmetic. HSAs and FSAs may cover prescribed medications and physician visits but generally won’t touch surgical procedures.

The Diagnosis Problem DTC Platforms Can’t Solve

Here’s my genuinely opinionated take: the biggest risk of DTC hair loss platforms isn’t side effects or pricing. It’s misdiagnosis.

A real dermatology workup includes patient history, family history, scalp examination, and trichoscopy (dermoscopy of the scalp, which reveals hair shaft diameter variability, empty follicular ostia, and density changes the naked eye misses). Selective labs like ferritin, TSH, vitamin D, and CBC get ordered when telogen effluvium is in the differential. The AAD doesn’t recommend routine androgen panels for men with classic pattern loss because the diagnosis is clinical, not hormonal.

Telehealth consultations, the kind both Hims and Keeps offer, are limited by what a physician can see through a phone camera in a three-minute interaction. That’s fine for a textbook Norwood III who just needs finasteride. It’s not fine for:

• Sudden diffuse shedding starting within the past six months (likely telogen effluvium, which needs workup of the trigger, not pattern-loss medications)
• Patchy, smooth bald spots (alopecia areata, an autoimmune condition with a completely different treatment pathway)
• Scalp pain, burning, redness, scaling, or visible scarring (possible scarring alopecias like lichen planopilaris or frontal fibrosing alopecia, which need prompt diagnosis before permanent follicle destruction)
• Women with irregular periods, acne, or excess body hair alongside thinning (warrants endocrine evaluation for PCOS or other androgen excess)
• Rapid progression of more than one Norwood stage per year in a young patient

The AAD’s position is that any progressive hair loss concerning to the patient is a legitimate reason for dermatology consultation. I’d go further: if you’re under 25 and losing hair fast, skip the subscription box and see someone in person first.

Lifestyle Factors: What’s Signal, What’s Noise

The peer-reviewed literature (primarily JAAD and the International Journal of Trichology) supports a few lifestyle conclusions. Most of them are less dramatic than Instagram would have you believe.

Smoking accelerates hair loss through microvascular damage, oxidative stress, and androgen effects. Cross-sectional studies show higher rates of androgenetic alopecia in smokers versus matched nonsmokers. This one is real.

Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding through telogen effluvium mechanisms. But iron supplementation in iron-replete patients doesn’t improve hair density. Don’t pop iron pills without bloodwork.

Vitamin D deficiency associates more strongly with alopecia areata than androgenetic alopecia, though severe deficiency may contribute to overall hair fragility per JAAD reviews. Supplement if you’re deficient. Don’t expect miracles.

Severe acute stress can trigger telogen effluvium two to three months after the event. It typically resolves within six to nine months, though it may unmask underlying pattern loss that was always coming.

Anabolic steroid use accelerates pattern loss in susceptible men through supraphysiologic androgen exposure, sometimes irreversibly.

Crash diets, severe caloric restriction, very low protein intake, and rapid weight loss all reliably produce telogen effluvium. This is one reason semaglutide patients sometimes report hair shedding. Modest dietary improvements beyond fixing specific deficiencies don’t produce visible hair benefits.

Sleep deprivation has been linked to elevated cortisol and altered circadian hair follicle regulation, but the clinical magnitude in normal adults is small. It’s not nothing, but it’s not the reason you’re thinning.

See also: Executive Reference Document Detailing 800000, 624130196, 8334172663, 934329570, 8007169711, 6033970660

FAQs

Can pattern hair loss be reversed? Partially, in some patients, with early treatment. Combination finasteride and minoxidil started before substantial follicular loss offers the best chance. Late-stage loss with extensive follicular dropout is generally not reversible with medical therapy alone.

Do biotin and collagen supplements help with hair loss? The evidence for biotin or collagen in patients without documented deficiency is weak. Biotin can also interfere with several common lab tests, including thyroid function and troponin assays, which creates a separate problem.

Are hair transplants permanent? Transplanted follicles from the genetically resistant donor zone generally retain that resistance and persist long-term. But the surrounding native hair may continue thinning, which is why most surgeons recommend continuing medical therapy after transplantation.

Is the Norwood scale used for women? No. Female pattern hair loss is classified using the Ludwig or Savin scales, which better capture the diffuse central thinning pattern more common in women.

Is hair loss covered by insurance? Pattern hair loss treatment is classified as cosmetic and generally not covered. Some HSA and FSA accounts cover prescribed medications and physician visits.

Does minoxidil work for everyone? No. Minoxidil produces visible improvement in roughly 40 to 60 percent of users in randomized trials, with response emerging at three to six months. Some patients lack sufficient sulfotransferase enzyme activity to convert minoxidil to its active form, which partly explains nonresponse.

How long do I need to stay on finasteride? Indefinitely, if you want to keep the results. Hair maintained by finasteride typically sheds within six to twelve months of stopping.

References

1. Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
2. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
3. Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
4. American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
5. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
6. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
7. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
8. Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
9. Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
10. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.

Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.

Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.